We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+15.64%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$580M
AUM Growth
+$11M
Cap. Flow
-$21.6M
Cap. Flow %
-3.73%
Top 10 Hldgs %
81.71%
Holding
22
New
–
Increased
4
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$9.23M
2
TTOO
T2 Biosystems, Inc
TTOO
+$3.29M
3
AIMT
Aimmune Therapeutics
AIMT
+$3.14M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$702K

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$15.8M
2
CMRX
Chimerix, Inc.
CMRX
+$9M
3
DERM
Dermira, Inc.
DERM
+$8.07M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$2.95M
5
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$367K

Sector Composition

Rank Sector Weight
1 Healthcare 70.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$108M 18.63%
3,796,362
+343,869
+10% +$9.23M
CEMP
2
DELISTED
Cempra, Inc.
CEMP
$68.3M 11.77%
2,193,060
– –
ZLTQ
3
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$60M 10.35%
2,103,528
-500,000
-19% -$15.8M
AIMT
4
DELISTED
Aimmune Therapeutics
AIMT
$55.2M 9.51%
2,990,000
+170,000
+6% +$3.14M
ESPR
5
DELISTED
Esperion Therapeutics
ESPR
$36.4M 6.28%
1,637,125
– –
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
$31M 5.34%
566
+61
+12% +$3.29M
AGRX
7
DELISTED
Agile Therapeutics
AGRX
$29.1M 5.02%
1,492
– –
ADMA icon
8
ADMA Biologics
ADMA
$1.94B
$29.1M 5.02%
3,608,171
– –
DERM
9
DELISTED
Dermira, Inc.
DERM
$28.4M 4.9%
820,823
-281,223
-26% -$8.07M
ARAV
10
DELISTED
Aravive, Inc. Common Stock
ARAV
$28.2M 4.87%
379,928
– –
ASXC
11
DELISTED
Asensus Surgical, Inc.
ASXC
$20.7M 3.57%
641,217
– –
CTLT
12
DELISTED
CATALENT, INC.
CTLT
$17.9M 3.09%
715,673
– –
CDTX
13
DELISTED
Cidara Therapeutics
CDTX
$17.5M 3.02%
50,973
– –
CYNA
14
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$15.6M 2.69%
1,021,381
+46,190
+5% +$702K
PRTK
15
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$12.9M 2.23%
682,680
– –
XENT
16
DELISTED
Intersect ENT, Inc
XENT
$7.88M 1.36%
350,000
– –
PTX
17
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$5.93M 1.02%
201,000
– –
CMRX
18
DELISTED
Chimerix, Inc.
CMRX
$4.23M 0.73%
472,943
-250,000
-35% -$9M
EVAR
19
DELISTED
Lombard Medical, Inc.
EVAR
$1.2M 0.21%
886,363
– –
ROKA
20
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$704K 0.12%
57,272
-23,917
-29% -$367K
SRNE
21
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$34K 0.01%
3,855
-350,000
-99% -$2.95M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Aisling Capital held 22 positions worth $580M, up 1.9% from $569M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Aisling Capital withdrew a net $21.6M in Q4 2015, reducing 5 holdings. Its largest reduction was ZELTIQ Aesthetics, Inc., cutting an estimated $15.8M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier.

Against the trend, Aisling Capital added an estimated $9.23M to Loxo Oncology, Inc.

  • Aisling Capital added most to Loxo Oncology, Inc in Q4 2015, an estimated $9.23M increase.
  • Aisling Capital's biggest Q4 2015 reduction was ZELTIQ Aesthetics, Inc., cutting an estimated $15.8M.
  • Aisling Capital's ten largest holdings make up 82% of its $580M portfolio in Q4 2015.
  • Aisling Capital opened 0 new positions and closed 0 in Q4 2015.
  • Aisling Capital's portfolio value rose 1.9% quarter-over-quarter to $580M.

Based on Aisling Capital's 13F filing for Q4 2015, filed 10 Feb 2016.